PMID- 21644933
OWN - NLM
STAT- MEDLINE
DCOM- 20120130
LR  - 20110803
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 78
IP  - 3
DP  - 2011 Sep
TI  - HLA-B35 correlates with a favorable outcome following adjuvant administration of 
      an HLA-matched allogeneic melanoma vaccine.
PG  - 203-7
LID - 10.1111/j.1399-0039.2011.01709.x [doi]
AB  - This work presents survival data of 42 melanoma patients at high risk for disease 
      recurrence who received an allogeneic melanoma vaccine composed of three cell 
      lines, each matching at least one allele of the recipient's human leukocyte 
      antigen (HLA)-A and -B loci. The 5-year overall survival (OS) rate and 
      disease-free survival (DFS) compared favorably with the standard interferon-alpha 
      regimen. Interestingly, patients bearing HLA-B35 had significantly better OS and 
      DFS (OS of 100% and DFS of 90% for HLA-B35 vs 56% and 23%, for the non-B35 
      patients). In contrast, patients expressing HLA-B07 did not fare well with the 
      vaccine. Although the data include a relatively small cohort of patients, it 
      strongly hints toward a correlation between HLA types and potential benefit from 
      anticancer immunotherapy.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Lotem, M
AU  - Lotem M
AD  - Sharett Institute of Oncology Laboratory of Tissue Typing, Hadassah Hebrew 
      University Medical Center, Jerusalem, Israel. mlotem@hadassah.org.il
FAU - Kadouri, L
AU  - Kadouri L
FAU - Merims, S
AU  - Merims S
FAU - Ospovat, I
AU  - Ospovat I
FAU - Nissan, A
AU  - Nissan A
FAU - Ron, I
AU  - Ron I
FAU - Frankenburg, S
AU  - Frankenburg S
FAU - Machlenkin, A
AU  - Machlenkin A
FAU - Israel, S
AU  - Israel S
FAU - Steinberg, H
AU  - Steinberg H
FAU - Hamburger, T
AU  - Hamburger T
FAU - Peretz, T
AU  - Peretz T
LA  - eng
PT  - Journal Article
DEP - 20110607
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-B35 Antigen)
RN  - 0 (Interferon-alpha)
RN  - 0 (Lymphokines)
RN  - 0 (allogenic effect factor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cancer Vaccines/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - HLA-B35 Antigen/*genetics/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Infant
MH  - Interferon-alpha/therapeutic use
MH  - Lymphatic Metastasis
MH  - Lymphokines
MH  - Male
MH  - Melanoma/immunology/pathology/*therapy
MH  - Middle Aged
MH  - Phenotype
MH  - Skin Neoplasms/immunology/secondary/*therapy
MH  - Survival Rate
MH  - Young Adult
EDAT- 2011/06/08 06:00
MHDA- 2012/01/31 06:00
CRDT- 2011/06/08 06:00
PHST- 2011/06/08 06:00 [entrez]
PHST- 2011/06/08 06:00 [pubmed]
PHST- 2012/01/31 06:00 [medline]
AID - 10.1111/j.1399-0039.2011.01709.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2011 Sep;78(3):203-7. doi: 10.1111/j.1399-0039.2011.01709.x. 
      Epub 2011 Jun 7.